|
Exports of bulk drugs and intermediates reported a growth of 4.56% in the first nine months of the current fiscal year on a YoY basis, reporting a trade surplus of almost $306.6 million for the period.
The bulk drugs and intermediates exports during the nine months from April to December, 2025 stood at $3.68 billion, as against $3.52 billion in the same period of last year. Quantity of exports grew 10.6% to 3,70,971.5 MT as against 3,35,413.7 MT during the comparable period.
The imports stood at $3.37 billion during April to December, 2025, as compared to $3.51 billion in the same period of previous fiscal year, according to data from the ministry of commerce and industry.
In rupee terms, the growth was almost 8.9% at Rs. 32,156.2 crore during the nine months ended December 31, 2025, as compared to Rs. 29,533.8 crore during the same period of last year.
Exports during the third quarter of the fiscal year declined 1.7%, while for the month of December, 2025, there was a growth of 3.27%.
During the quarter from October to December 2025, exports declined to $1.21 billion on a YoY basis, compared to $1.23 billion. Quantity of exports grew 7.40% to 1,29,054.8 MT compared to 1,20,159.2 MT during the same quarter a year ago.
In rupee terms, there was a growth of 3.8% during the quarter, at Rs. 10,830.9 crore as against Rs. 10,437.8 crore reported in the third quarter of last fiscal year.
Exports during the month of December, 2025 was at $442.18 million compared to $428.16 million during the same month of last year. Quantity of exports grew 17.5% to 47,132.76 MT as against 40,114.66 MT on a YoY basis.
In rupee terms, the growth was 9.44% to Rs. 3,983.62 crore compared to Rs 3,638.8 crore reported in December, 2024.
As reported earlier, the exports during the financial year ended March, 2025 reported a 2.3% growth to $4.9 billion, as compared to $4.79 billion in the previous fiscal year. Quantity, on the other hand, declined 3.2% to 4,59,449 MT as compared to 4,74,617 MT reported during April, 2023 to March, 2024.
The Central government has been emphasising on reducing the imports of essential pharmaceutical raw materials such as bulk drugs, drug intermediates and key starting materials, among others, and has initiated various incentive schemes to support domestic production of these materials.
The Department of Pharmaceuticals has been promoting production of pharma raw materials in the country, including through a production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates and active pharmaceutical ingredients (APIs) in the country, to support the industry in various aspects regarding ease of doing business and availing the benefits of the scheme.
It has also announced schemes to promote bulk drug parks in the country, as part of its efforts to promote domestic manufacturing of pharma ingredients.
|